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Abstract
Background: Selective serotonin-reuptake inhibitors (SSRIs) are commonly prescribed for the
treatment of depression and can be used as nonhormonal alternatives to manage hot flashes for
women with a history of breast cancer and unable to take hormone replacement therapy. There
are, however, few reports on the efficacy of SSRIs for the treatment of natural postmenopausal
climacteric symptoms. In this pilot study, we evaluate the SSRI, fluvoxamine, for controlling
climacteric symptoms and vasomotor symptoms, in particular.
Methods: Twenty-two patients were enrolled from our hospital. All were orally administered
fluvoxamine (50 mg daily). Climacteric and depressive symptoms were assessed using simple
menopausal index (SMI) and self-rating questionnaire for depression (SRQ-D), respectively, at
baseline, and at 2 and 6 weeks post-treatment.
Results: Six weeks following drug administration, neither the SRQ-D nor SMI scores significantly
decreased compared to baseline. The mean levels of vasomotor symptoms and mental symptoms
decreased significantly following fluvoxamine administration, while skeletal muscle symptom scores
did not.
Conclusion: We were able to demonstrate that fluvoxamine was effective in treating not only
depressive moods in climacteric symptoms but also the associated vasomotor symptoms. There
are several limitations to this preliminary study. Future controlled studies are needed to further
evaluate the efficacy of fluvoxamine for climacteric disturbances.
Background
Perimenopause is an estrogen-deficient state often associ-
ated with vasomotor symptoms including hot flashes,
night sweats, and vaginal dryness. Hormone replacement
therapy (HRT) is effective in reducing the incidence and
severity of vasomotor symptoms by as much as 80% [1].
For quite some time, HRT has been the gold standard
treatment for climacteric symptoms. However, despite the
robust evidence supporting its use for hot flashes, recent
findings from the Women's Health Initiative (WHI) Study
suggest that combined conjugated equine estrogen and
progestin therapy cannot be recommended to most
women, as it increases the risks for coronary heart and
thromboembolic disease [2,3]. Therefore, nonhormonal
alternative treatments are needed.
Serotonin levels in the brain of postmenopausal women
are lower than in women who have not yet entered men-
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opause [4]. Thus, it is thought that the serotonergic system
plays a major role in menopause.
Selective serotonin-reuptake inhibitors (SSRIs) are com-
monly prescribed for the treatment of depression. Several
studies have found SSRIs improve the incidence of hot
flashes and other menopausal symptoms in women with
breast cancer [5,6]. Stearns et al. evaluated that the SSRI
paroxetine, may be an effective and acceptable alternative
to HRT and other therapies in treating menopausal hot
flash symptoms [7]. In 1999, fluvoxamine was the first
antidepressant SSRI introduced in Japan. It is an effective
treatment for postpartum depression [8]. To date, there
are no reports of fluvoxamine used as an effective mono-
therapy for vasomotor symptoms such as hot flashes. The
aim of this study was to investigate whether fluvoxamine
is an effective treatment for these spontaneous climacteric
symptoms.
Methods
Twenty-two patients who presented to our climacteric
outpatient clinic on Dokkyo University School of Medi-
cine were enrolled. They were classified as either perimen-
opausal (N = 8) and postmenopausal (N = 14).
Perimenopausal status was defined as having irregular
menstrual cycles (fewer than six menstrual cycles per year)
and follicle-stimulating hormone (FSH) levels greater
than 20 IU/liter, documenting declining ovarian function.
Postmenopausal status was defined as being amenorrheal
for 12 months or more, or having had a bilateral
oophorectomy. Clinical climacteric and depressive symp-
toms were assessed at study entry using the simple meno-
pausal index (SMI) and Self-rating Questionnaire for
Depression (SRQ-D).
SMI, a questionnaire with the ten most common climac-
teric symptoms for Japanese perimenopausal women, was
used to identify the symptoms and to determine severity
before treatment. A full score of SMI is one hundred. SMI
scores of each group were classified according to three
subgroups of climacteric symptoms; vasomotor, mental,
and skeletal muscle, and then assessed according to sever-
ity (severe, moderate, mild, free) (Table 1). We used the
SRQ-D to evaluate depressive moods. A full score of SRQ-
D is 36 points. Those women with an SRQ-D score >12
were regarded as having depressive symptoms. The SRQ-
D is suitable for evaluating masked depression; it includes
many questions concerning depression-related physical
symptoms, where a score of 11 indicates possible
depression [9,10].
All patients were administered fluvoxamine
(DEPROMEL®; Meiji Seika Kaisha, Japan) 50 mg daily
orally. Climacteric and depressive symptom assessments
were repeated 2 and 6 weeks after treatment using the SMI
and SRQ-D. Informed consent was obtained from all
patients, and the research procedure was approved by the
local ethics committee. Exclusion criteria included medi-
cal illness, use of psychoactive drugs within 3 months
before assessment, abnormalities on screening ultra-
sounds, and clinical contraindications to antidepressant
therapy.
All data are expressed as mean values ± SE. Statistical anal-
ysis was performed where appropriate by using SPSS soft-
ware version 8.0 (SPSS Inc., Chicago, IL). Analytical tests
were repeated measures ANOVA (Figure 1, Figure 2A),
and paired t-test (Figure 2B). P-values less than 0.05 were
considered statistically significant.
Results
Medical characteristics
A total of 22 women participated in the pilot trial, where
the mean age was 52.9 ± 7.6 years old. All women were
Changes in the SRQ-D scores Figure 1
Changes in the SRQ-D scores. Changes in the SRQ-D 
scores at baseline, after 2, and 6 weeks of fluvoxamine treat-
ment. Values are expressed as mean ± SE, where *P < 0.05 vs 
baseline.
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Table 1: Items used for the simple menopausal index (SMI)
severe moderate mild free
1. Hot flushes 10 6 3 0
2. Episodic sweating 10 6 3 0
3. Cold limbs 14 9 5 0
4. Heart discomfort 12 8 4 0
5. Sleeping disorders 14 9 5 0
6. Irritability 12 8 4 0
7. Depression 7 5 3 0
8. Headache 7 5 3 0
9. Fatigue 7 4 2 0
10. Shoulder stiffness/lumbago 7 5 3 0
SMI scores of climacteric symptoms for the three subgroups. Each 
group composed of vasomotor symptoms (No. 1 to 4), mental 
symptoms (No. 5 to 8), and skeletal muscle symptoms (No. 9 and 
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evaluated for safety and tolerability. Pretreatment SRQ-D
scores were 17.3 ± 1.3 and SMI scores were 68.5 ± 4.2.
Additional medical information for the study participants
are listed in Table 2. Four women prescribed fluvoxamine
discontinued drug therapy due to adverse effects (nausea
2, mouth dryness 1, dizziness 1).
Reduction of depressive symptoms
Depressive symptoms were moderately severe at baseline
(median SRQ-D scores = 17.3 ± 1.3). SRQ-D scores after 2
weeks of treatment were significantly decreased compared
with that at baseline. Similarly, fluvoxamine improved
SRQ-D scores after 6 weeks (P  < 0.05, Figure 1). All
patients had a SRQ-D score >13 at the start of treatment,
and five patients had decreased SRQ-D scores (SRQ-D
<11) under normalization after 6 weeks of treatment.
Reduction of SMI scores
SMI scores expressed clinically climacteric symptoms,
including mental symptoms. Following fluvoxamine
administration at week 6, SMI scores declined to 50.1 ±
7.1 from baseline (P < 0.05, Figure 2A). Furthermore, we
performed a detailed investigation for SMI score. SMI
scores were divided into three subgroups of climacteric
symptoms, vasomotor, mental and skeletal muscle symp-
toms. The mean levels of vasomotor and mental symp-
toms decreased significantly following fluvoxamine
administration (P < 0.05, Figure 2B). However, there was
no statistically significant difference between pre and post
treatment of skeletal muscle symptoms (lumbago and
general fatigue).
Discussion
In this study we demonstrated the effectiveness of fluvox-
amine on climacteric symptoms. Climacteric symptoms
occur in association with menopause. Drastic changes in
hormone levels occur during perimenopause [11]. It was
reasonable to assume that climacteric symptoms are
caused by low levels of sex hormones. Most reports show
that HRT has a beneficial effect on climacteric symptoms
[12,13]. Vasomotor symptoms, in particular hot flashes,
are the most common complaint among women entering
menopause. The physiology behind vasomotor symp-
toms is not fully understood, although the main underly-
ing cause is thought to be a disturbance in normal
thermoregulatory function. Given that there are strong
interactions with estrogen reduction and vasomotor
symptoms, some menopausal women would benefit from
estrogen to alleviate their vasomotor symptoms.
The WHI single-arm study, however, showed HRT
increased the occurrence of breast cancer and myocardial
infarction in comparison with placebo control [2]. There-
fore, nonhormonal treatments include alternative treat-
ments for menopause-related symptoms, and ultimately
improvements in quality of life. It is possible SSRIs can be
used to treat vasomotor symptoms since there is a strong
interaction between estrogen and the serotonergic system
[14]. Recent clinical studies of venlafaxine and fluoxetine
in women with a prior history of breast cancer have sug-
gested that certain antidepressants, with the ability to
inhibit serotonin reuptake, may significantly reduce the
vasomotor symptoms associated with menopause
[5,6,15]. The SSRI fluvoxamine is an effective antidepres-
sant that acts by facilitating serotonergic neurotransmis-
sion [16,17]. In our fluvoxamine trials, the SSRI showed
beneficial effects; that is an improvement in vasomotor
and mental symptoms appeared statistically significant in
accordance to other SSRI reports.
HRT's inability to deal with symptoms of general fatigue
and lumbago has been documented [18,19]. As Weitzner
Table 2: Characteristics of the patients
Number of patients 22
Peri menopause 8
Post menopause 14
Age (yr) 52.9 ± 7.6
BMI 22.6 ± 2.7
FSH (mIU/ml) 80.8 ± 42.4
SRQ-D score 17.3 ± 1.3
SMI score 68.5 ± 4.2
Characteristics of patients (N = 22) receiving fluvoxamine at start of 
trial. Shown are mean ± SE.
A – Changes in the simple menopausal index (SMI) Figure 2
A – Changes in the simple menopausal index (SMI). 
Changes in the simple menopausal index (SMI) at baseline, 
after 2, and 6 weeks of treatment with fluvoxamine, where *P 
< 0.05 vs baseline. B – Percent of change from baseline 
among subgroups according to SMI Percent of change 
from baseline among subgroups according to SMI at 6 weeks 
of fluvoxamine treatment, where *P < 0.05 vs baseline; NS: 
No significant change.
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et al. demonstrated most SSRI treatment for breast cancer
in women with hot flashes had significant improvement
in their general levels of fatigue, as well as their emotional
and mental levels of fatigue [20]. Our results suggest that
fluvoxamine treatment was unsuccessful (p > 0.05) for
general fatigue and lumbago accompanied by climacteric
symptoms, potentially due to the limited power of statis-
tical analyses from the small sample size and dose. Also,
it is possible the SSRIs may be ineffectual for skeletal mus-
cle symptoms; given the high frequency of general fatigue
and lumbago, and that SSRIs are insufficient in relieving
these symptoms.
Although this study is limited by its uncontrolled design
and small sample size, our data suggests fluvoxamine,
along with other SSRIs, decreases the level of depressive
climacteric disturbances. The pathophysiology of meno-
pausal mood disorders remains to be determined; how-
ever, sex specificity suggests that hormones have an
impact on the incidence of depression [21]. The absence
of estrogen in the brain during menopause results in
decreased release of serotonin from the neurons and a
negative mood state, including irritability and depression
[22]. As a result, medications such as SSRIs cause serot-
onin to remain in the synapse longer, thus leading to
amelioration in negative mood states caused by a decrease
in estrogen [23].
Conclusion
In summary, although these data are preliminary and
there are several limitations to this study, we were able to
demonstrate that the SSRI, fluvoxamine, was effective in
treating depressive moods associated with menopause.
Our data also suggests improvements in vasomotor and
mental symptom. Future studies using larger groups of
patients are necessary to assess the relative effectiveness
and morbidity of this treatment option.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
AO conceived of this study, and performed the statistical
analysis and drafted the manuscript. YM conceived of the
study, and participated in its design and coordination and
helped to draft the manuscript. RO helped the statistical
analysis. NI conceived of the study, and participated in its
design and coordination. All authors read and approved
the final manuscript. All authors contributed equally to
this work.
References
1. Greendale GA, Lee NP, Arriola ER: The menopause.  Lancet 1999,
353:571-580.
2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C,
Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC,
Kotchen JM, Ockene J, Writing Group for the Women's Health Initia-
tive Investigators: Risks and benefits of estrogen plus progestin in
healthy postmenopausal women: principal results From the
Women's Health Initiative randomized controlled trial.  JAMA
2002, 88:321-333.
3. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black
H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass
M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson
R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D,
Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sul-
livan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE,
Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R,
Wassertheil-Smoller S, Women's Health Initiative Steering Committee:
Effects of conjugated equine estrogen in post menopausal
women with hysterectomy: the Women's Health Initiative
randomized controlled trial.  JAMA 2004, 291:1701-1712.
4. Gonzales GF, Carillo C: Blood serotonin levels in postmenopau-
sal women ; effect of age and serum oestradiol therapy levels.
Maturitas 1993, 17:23-29.
5. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Hal-
yard MY, Pruthi S, Novothy PJ, Rummans TA: Phase III evaluation of
fluoxetine for treatment of hot flashes.  J Clin Oncol 2002,
20:1578-1583.
6. Stearns V, Isaacs C, Rowland J, Crawford J, Ellis MJ, Kramer R, Law-
rence W, Hanfelt JJ, Hayes DF: A pilot trial assessing the efficacy
of paroxetine hydrochloride (Paxil) in controlling hot flashes
in breast cancer survivors.  ANN ONCOL 2000, 11:17-22.
7. Stearns V, Beebe KL, Iyengar M, Dube E: Paroxetine controlled
release in the treatment of menopausal hot flashes.  JAMA 2003,
289:2827-2834.
8. Suri R, Burt VK, Altshuler LL, Zuckerbrow-miller J, Fairbanks L: Flu-
voxamine for postpartum depression.  Am J Psychiatry 2001,
158:1739-1740.
9. Zung WWK: A self-rating depression scale.  Arch Gen Psychiatry
1965, 12:63-70.
10. Rockliff BW: A brief self-rating questionnaire for depression
(SRQ-D).  Psychosomatics 1969, 10:236-243.
11. Blumenthal SJ: Women and depression.  J Womens Health Gend
Based Med 1994, 3:467-479.
12. Holinka CF, Pickar JH: Clinical studies in hormone replacement
therapy: Treatment of the postmenopausal woman.  2nd edi-
tion. Edited by: Lobo RA. Philadelphia: Lippincott Williams & Wilkins;
2002:629-637. 
13. Kronenberg F: Hot flashes: phenomenology, quality of life, and
search for treatment options.  Exp Gerontol 1994, 29:319-336.
14. Sherwin BB: The impact of different doses of estrogen and pro-
gestin on mood and sexual behavior in postmenopausal
women.  J Clin Endocrinol Metab 1991, 72:336-343.
15. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL,
Novotny PJ, Dakhil SR, Rodger K, Rummans TA, Christensen BJ: Ven-
lafaxine in management of hot flashes in survivors of breast
cancer: a randomized controlled trial.  Lancet 2000,
356:2059-2063.
16. Ware MR: Fluvoxamine: A review of the controlled trial in
depression.  J Clin Psychiatry 1997, 58(Suppl 5):15-23.
17. Classen V: Review of the animal pharmacology and pharmacok-
inetics of fluvoxamine.  Br J Clin Pharmacol 1983, 15(Suppl
3):49s-55s.
18. Fuyuki T, Ohta H, Makita K, Takamatsu K, Horiguchi F, Nozawa S:
Hormone replacement therapy on climacteric symptoms.
Obstet Gynecol Ther 1998, 76(suppl):158-165.
19. Pan B, Kato Y, Sengoku K, Takuma N, Niizeki N, Ishikawa M: Treat-
ment of climacteric symptoms with herbal formulas of tradi-
tional Chinese medicine.  Gynecol Obstet Invest 2004, 57:144-148.
20. Weitzner MA, Moncello J, MSN , ARNP , Jacobsen PB, Minton S: A
pilot trial of Paroxetine for the treatment of hot flashes and
associated symptoms in women with breast cancer.  J Pain Symp-
tom Manag 2002, 23:337-345.
21. Sherwin BB, Suranyi-Cadotte BE: Up-regulatory effect of estrogen
on platelet 3H-imipramine binding sites in surgically meno-
pausal women.  Biol Psychiatry 1990, 28:339-348.
22. Backstrom T: Symptoms related to the menopause and sex
steroid treatments.  Ciba Found Symp 1995, 191:171-180.
23. Stahl SM: Essential psychopharmacology: neuroscientific basis
and practical applications.  Cambridge UK: Cambridge University
Press; 1996. 